Such validations should include, at least, the V600E mutation in the BRAF gene, indicating which malignant melanoma patients respond effectively to vemurafinib treatment [5], [6], mutations of the EGFR gene to predict which lung adenocarcinomas respond to tyrosine kinase inhibitor (TKI) treatment, primarily those identified in amino acid (aa)719 exon 18, exon 19 deletions, aa768 exon 20 and aa858 exon 21 [7], [8], and KRAS mutations in exon 2 (codon 12 and 13) to predict lack of response to targeted monoclonal antibodies in colorectal cancer [9]. This evidence concerns the gene KRAS and colorectal cancer.